TR200100609T1 - Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik - Google Patents

Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik

Info

Publication number
TR200100609T1
TR200100609T1 TR2001/00609T TR200100609T TR200100609T1 TR 200100609 T1 TR200100609 T1 TR 200100609T1 TR 2001/00609 T TR2001/00609 T TR 2001/00609T TR 200100609 T TR200100609 T TR 200100609T TR 200100609 T1 TR200100609 T1 TR 200100609T1
Authority
TR
Turkey
Prior art keywords
pharmaceutical
related compound
liquid hammer
balanced
hammer form
Prior art date
Application number
TR2001/00609T
Other languages
English (en)
Inventor
Sawai Seiji
Kasai Akihiro
Otomo Kazumi
Original Assignee
Fujisawa Pharmaceutical Co.,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200100609(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co.,Ltd. filed Critical Fujisawa Pharmaceutical Co.,Ltd.
Publication of TR200100609T1 publication Critical patent/TR200100609T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Eczacilikla ilgili sivi çekici formda, dengelenmis bir bilesigin içerigi: Kendi kendini tahdit eden bir polipeptid bilesigi, R1'in bir hidrojen atomu veya bir organik asitten hidroksil grubunun ayrilmasi ile meydana gelen bir radikal ve R2 ve R3'ün, ayni ya da farkli, bir hidrojen atomu ya da bir hidroksil grubu, veya bir tuz ve bir polisakarid, bir disakarid ve sodyum klorid'den olusan bir gruptan seçilmis bir dengeleyici oldugu, genel bir formülle(I) ifade edilmistir.
TR2001/00609T 1999-07-01 2000-06-29 Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik TR200100609T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18771399 1999-07-01

Publications (1)

Publication Number Publication Date
TR200100609T1 true TR200100609T1 (tr) 2001-07-23

Family

ID=16210881

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00609T TR200100609T1 (tr) 1999-07-01 2000-06-29 Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik

Country Status (28)

Country Link
US (2) US6774104B1 (tr)
EP (1) EP1107777B1 (tr)
JP (2) JP3381722B2 (tr)
KR (1) KR100454784B1 (tr)
CN (2) CN1179748C (tr)
AR (1) AR024634A1 (tr)
AT (1) ATE280583T1 (tr)
AU (1) AU752265B2 (tr)
BR (2) BRPI0006823B8 (tr)
CA (1) CA2341568C (tr)
CZ (1) CZ295720B6 (tr)
DE (1) DE60015279T2 (tr)
ES (1) ES2225161T3 (tr)
HK (1) HK1040057B (tr)
HU (1) HU229089B1 (tr)
ID (1) ID29468A (tr)
IL (2) IL141455A0 (tr)
MX (1) MXPA01000601A (tr)
NO (1) NO330353B1 (tr)
NZ (1) NZ510290A (tr)
OA (1) OA11601A (tr)
PL (1) PL200141B1 (tr)
PT (1) PT1107777E (tr)
RU (1) RU2251411C2 (tr)
TR (1) TR200100609T1 (tr)
TW (1) TWI233805B (tr)
WO (1) WO2001002002A1 (tr)
ZA (1) ZA200101589B (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
AU2003252746A1 (en) 2002-07-31 2004-02-16 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
MXPA05005338A (es) * 2002-11-18 2005-12-14 Vicuron Pharm Inc Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
EP1721610B1 (en) 2004-03-04 2009-05-13 Eisai R&D Management Co., Ltd. Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
US7514450B2 (en) * 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
AU2005306579B2 (en) * 2004-11-22 2012-01-19 Immuron Limited Bioactive compositions
KR101307999B1 (ko) 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
WO2007010995A1 (ja) * 2005-07-20 2007-01-25 Kyowa Medex Co., Ltd. 生体試料中のペプチドの安定化方法
CN1962852B (zh) * 2006-11-27 2011-11-09 西北农林科技大学 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
PE20150683A1 (es) * 2012-05-22 2015-06-03 Paion Uk Ltd Composiciones que comprenden benzodiazepinas de accion corta
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
DK2893929T3 (da) 2013-03-15 2025-07-07 Merck Sharp & Dohme Llc Antibiotisk ceftolozansammensætninger
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
CN103330932B (zh) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 一种米卡芬净或其盐的药物组合物
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
EP3003298B1 (en) * 2013-06-05 2024-03-20 The University Of British Columbia Anti-fibrogenic compounds, methods and uses thereof
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101611349B1 (ko) 2014-04-14 2016-04-12 신우철 안정성이 개선된 밀크씨슬 엑스의 제형
JP7109189B2 (ja) * 2014-05-29 2022-07-29 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッド シクロペプチド系化合物の組成物およびその製造方法と使用
RU2732129C2 (ru) * 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
ES2777942T3 (es) * 2014-12-31 2022-04-22 Galenicum Health S L U Composiciones farmacéuticas estables que comprenden micafungina
ES2694561T3 (es) 2015-02-23 2018-12-21 Selectchemie Ag Composición de anidulafungina
EP3554474B1 (en) 2016-12-16 2023-12-06 Baxter International Inc. Micafungin compositions
WO2019005829A1 (en) * 2017-06-26 2019-01-03 Wayne State University METHODS AND COMPOSITIONS RELATING TO CANCER DEPENDENT ON HORMONE RECEPTORS
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
IE990233A1 (en) * 1990-06-18 2000-11-15 Fujisawa Pharmaceutical Co New Polypeptide Compound and a Process for Preparation thereof
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
RU2095081C1 (ru) * 1991-12-13 1997-11-10 Акционерное общество "Биофа" Фармацевтическая композиция антивирусного действия
JPH0651641A (ja) 1992-07-30 1994-02-25 Olympus Optical Co Ltd 湿式現像装置
JPH06172204A (ja) * 1992-12-09 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja) 1993-02-25 2001-12-25 ソニー株式会社 偏平型陰極線管の画像歪補正装置
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
AU681119B2 (en) * 1993-05-17 1997-08-21 Fujisawa Pharmaceutical Co., Ltd. New polypeptide compound and a process for preparation thereof
WO1996011210A1 (en) * 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
DE69739532D1 (de) * 1996-03-08 2009-09-24 Astellas Pharma Inc Prozess für die deacylierung von zyklischen lipopeptiden.
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
JPH09301997A (ja) 1996-05-17 1997-11-25 Yamanouchi Pharmaceut Co Ltd 新規環状ペプチド系化合物
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JPH10279498A (ja) * 1997-04-07 1998-10-20 Nippon Shinyaku Co Ltd 慢性関節リウマチ治療剤
JP3544847B2 (ja) * 1998-01-16 2004-07-21 三菱電機株式会社 光学的情報再生方法および装置
EP1582204B1 (en) * 1999-03-03 2013-09-25 Eli Lilly & Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
WO2000051567A1 (en) * 1999-03-03 2000-09-08 Eli Lilly And Company Processes for making pharmaceutical oral ecb formulations and compositions
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent

Also Published As

Publication number Publication date
DE60015279D1 (de) 2004-12-02
JP4691866B2 (ja) 2011-06-01
EP1107777A1 (en) 2001-06-20
HK1080724A1 (zh) 2006-05-04
KR100454784B1 (ko) 2004-11-05
MXPA01000601A (es) 2002-04-08
NO20010893L (no) 2001-04-24
HUP0103740A2 (hu) 2002-02-28
IL141455A0 (en) 2002-03-10
HK1040057A1 (en) 2002-05-24
CN1636591A (zh) 2005-07-13
US6774104B1 (en) 2004-08-10
JP3381722B2 (ja) 2003-03-04
BRPI0006823B1 (pt) 2020-01-07
CZ20011186A3 (cs) 2001-09-12
JP2002363097A (ja) 2002-12-18
AU5572200A (en) 2001-01-22
NZ510290A (en) 2003-07-25
CA2341568A1 (en) 2001-01-11
RU2251411C2 (ru) 2005-05-10
EP1107777B1 (en) 2004-10-27
AU752265B2 (en) 2002-09-12
CN100352495C (zh) 2007-12-05
AR024634A1 (es) 2002-10-16
CN1179748C (zh) 2004-12-15
DE60015279T2 (de) 2005-05-25
CN1315865A (zh) 2001-10-03
US7112565B2 (en) 2006-09-26
ATE280583T1 (de) 2004-11-15
WO2001002002A1 (en) 2001-01-11
PT1107777E (pt) 2005-01-31
HK1040057B (zh) 2005-08-05
US20040157769A1 (en) 2004-08-12
BR0006823A (pt) 2001-06-05
KR20010072903A (ko) 2001-07-31
PL200141B1 (pl) 2008-12-31
ZA200101589B (en) 2002-09-02
OA11601A (en) 2004-07-30
NO20010893D0 (no) 2001-02-22
TWI233805B (en) 2005-06-11
JP2003503462A (ja) 2003-01-28
HUP0103740A3 (en) 2002-08-28
NO330353B1 (no) 2011-04-04
HU229089B1 (en) 2013-07-29
IL141455A (en) 2006-12-31
CA2341568C (en) 2011-10-25
PL346297A1 (en) 2002-01-28
ID29468A (id) 2001-08-30
ES2225161T3 (es) 2005-03-16
CZ295720B6 (cs) 2005-10-12
BRPI0006823B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
TR200100609T1 (tr) Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik
KR930002325A (ko) 피리미딘 유도체
BR0116004A (pt) Derivados de 6-o-carbamoil cetolida de eritromicina úteis como antibacterianos
AR018633A1 (es) Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo
WO2002046170A8 (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
DK0861228T3 (da) Lipopolyaminer som transfektionsmidler samt deres farmaceutiske anvendelser
MX9801129A (es) Agentes farmaceuticos.
GB2408609A (en) Modular financial service instrument
IL124537A0 (en) Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same
ATE168685T1 (de) Aminoheterocyclische derivate als antithrombotische oder antikoagulierende mittel
EP1420026A3 (en) Use of conjugates of phytosterol or phytostanol with ascorbic acid in treating or preventing cardiovascular disease, and compositions thereof
FR2835749B1 (fr) Composition pharmaceutique ameliorant le transfert de gene in vivo
DE60005501D1 (de) 4'-c-ethynyl-pyrimidine nukleoside
FI971935A0 (fi) Polyanioniset bentsyyliglykosidit sileän lihaskudoksen solujen lisääntymisen estäjinä
BR0014199A (pt) Derivados de bifenila como inibidores de nhe-3
NO984470L (no) Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase
ATE479425T1 (de) Sialsäure-derivate enthaltende feste dispersion
GB1487980A (en) Suspension of xanthan gum
BR0214748A (pt) Derivados 6-oacil-cetolidas de eritromicina, úteis como antibacterianos
DE60117248D1 (de) Parenterale lösung enthaltend amiodaron
NO20020969L (no) Fremgangsmåte ved fremstilling av gallesyrederivater
DK1102594T3 (da) Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant
NO20041671L (no) Anthelmintic composition
KR960014092A (ko) 이미노카르본산염 수용액 조성물 및 이미노카르본산염의 취급방법